© 2022 Sema4 OpCo, Inc. All rights reserved.
Explore new frontiers in the evolving
biopharma landscape with Sema4
Unlock the power of big data and advance
next-generation precision medicine
Biopharma companies require access to high quality patient data to scale precision medicine initiatives. While vast amounts of patient data are available, they are not effectively leveraged to understand disease and wellness. Advanced data engineering and data science approaches are needed to span this divide.
Sema4 is uniquely positioned to deliver value at the pre-clinical, clinical, and commercial drug development stages for biopharma companies. With its world-leading expertise and capabilities complemented by an interdisciplinary team of scientists, clinicians, and data engineers powered by one of the leading genomics laboratories in the world Sema4 can help you discover new possibilities and blaze new trails across your drug lifecycle.
Learn how our biopharma partners are pushing the boundaries
across research and development with Sema4
Strategic partnership to leverage shared experiences in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery
Research partnership to demonstrate the value of precision medicine for drug screening
Strategic partnership on the largest prospective Asthma study of its kind to provide new insights on the complex disease using advanced network modeling
Unique patient-centered intelligence across your drug lifecycle
With Sema4 as your partner, you can confidently discover what’s possible and blaze new trails across your research, development, and commercialization efforts to get treatments and therapies to the market faster, safer, and cheaper. See below to learn about the three specific ways Sema4 can provide incremental value to your organization.
Advance drug discovery
by leveraging state-of-the-art genomic infrastructure to generate, analyze, and interpret molecular data
State-of-the-art genomic infrastructure to support a suite of molecular, cytogenic and biochemical tests
Two CLIA-certified and CAP accredited laboratories
Over 500,000 next-generation sequencing panels accessioned
Improve clinical trial productivity
by combining rich molecular data with deeply curated clinical data
SaaS solutions built using deep longitudinal clinicogenomic datasets across multiple TAs
Solutions driven by Sema4’s direct engagement with patients and providers
Workflow support and solutions to increase site efficiencies
Connect the Dots
from research through commercialization with differentiated, AI-powered insights
Access to millions of deidentified patients’ worth of clinical, molecular, imaging, and genetic data
Advanced data engineering and NLP-driven data curation with industry leading expertise in network modeling
Data science expertise for a full spectrum of RWD analyses
Achieve success across early drug discovery to development through
commercialization using best-in-class end-to-end Sema4 solutions
Sema4 offers tools and expertise to transform an ocean of raw data into powerful information to help answer questions fundamental to the Biopharma industry. From models that can optimize the design of a Phase III rare disease trial, to leveraging real-world evidence to enable development of digital trials, to key mechanistic insights regarding disease subtypes, we can generate the strategic answers to power your drug development pipeline.
Contact us today to learn more about how we can help you.
Discovery
Research
Lead Identification
Drive increased probability of success and terminate bad molecules sooner
Development
Preclinical
Phase I
Early Clinical
Reduce trial duration, minimize dose finding / escalation, better patient selectivity
Development
Phase II
Phase III
Protocol Optimization
Maximize trial opportunity, decrease time to market, and optimize market access
Commercialization
Phase IV/RWE
Real World Data
Characterize patient journeys and diagnostic odysseys
Read Sema4’s article, “Demystifying Autoimmune Diseases Using Patient-Centered Health Intelligence” in the March issue of GEN Magazine (Genetic Engineering and Biotechnology News). The article discusses our work on building predictive models to better under autoimmune diseases and how to treat them.
Resources
